MindImmune Therapeutics Receives Grant for Alzheimer’s Treatment

Scientists working on MITI-101 research at MindImmune Therapeutics.

News Summary

MindImmune Therapeutics has been awarded a grant from the Rhode Island Life Science Hub to advance preclinical development of MITI-101, a monoclonal antibody aimed at combating neuroinflammation in Alzheimer’s disease. This funding supports laboratory efforts to inhibit the recruitment of immune cells implicated in neuroinflammatory damage, addressing a critical need for innovative therapies in Alzheimer’s treatment. MindImmune, established with backing from various investors, seeks to progress MITI-101 and enhance disease management in Alzheimer’s and other neurodegenerative disorders.

Rhode Island – MindImmune Therapeutics, a biopharmaceutical company specializing in neuroinflammation and Alzheimer’s disease, has been awarded a grant from the Rhode Island Life Science Hub to expedite the preclinical development of MITI-101, a monoclonal antibody designed to combat the disease. This grant signifies a crucial step for the company as it seeks to advance its innovative treatment solutions for Alzheimer’s, which has been a growing public health concern.

The funding will specifically support the ongoing laboratory efforts for MITI-101, which aims to inhibit the recruitment of neuro-inflammatory innate immune cells into the brain. By doing so, the antibody seeks to reduce neuroinflammatory damage, which is increasingly recognized as a contributing factor in the progression of Alzheimer’s disease.

Recent therapies available for Alzheimer’s have provided only modest clinical benefits and often come with significant side effects. This underlines the pressing need for new, effective treatment options centered around the immune system’s role in the disease. MITI-101 differentiates itself by targeting CD11c, a subunit of the complement receptor 4 (CR4) present in the bloodstream. Studies have indicated that the CD11c+ cells contribute to neuroinflammation and can damage synaptic connections, essential for cognitive function.

Research suggests that preventing the infiltration of CD11c+ cells into the brain could halt the neuroinflammatory damage evident in many Alzheimer’s patients. MindImmune’s commitment is to revolutionize Alzheimer’s treatment and expand its implications to other neurodegenerative disorders.

Company Background and Funding

MindImmune was established in collaboration with the Ryan Institute for Neuroscience Research at the University of Rhode Island. Since its inception, the company has successfully raised $19.4 million in funding to date, supported by a mix of venture capitalists and organizations, including Dolby Family Ventures, Pfizer Ventures, and the Alzheimer’s Drug Discovery Foundation (ADDF).

The grant from the Rhode Island Life Science Hub is a critical catalyst for the company, further asserting its mission to provide early efficacy results for MITI-101 in Alzheimer’s patients. Currently, MindImmune is diligently working towards attracting additional investment to propel MITI-101 into real-world clinical development.

The Need for Innovative Treatments

Alzheimer’s disease impacts millions of individuals and their families, demanding a shift toward more effective treatment frameworks. Existing therapies have limited effectiveness, prompting researchers to explore new avenues. Neuroinflammation has emerged as a focal point for many in the scientific community, revealing the immune system’s potential role in disease management. MindImmune is at the forefront of this pivotal research and development.

MindImmune Therapeutics, through its continuous commitment and acquisition of financial support, is poised to make significant strides in the fight against Alzheimer’s disease. As MITI-101 progresses, it may lead to broader implications for treating neurodegenerative diseases, thereby transforming the current treatment landscape.

For media inquiries regarding MindImmune Therapeutics, Danielle Duchene from Inizio Evoke Comms is the designated contact.